Article Information
History
- March 8, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Kayoko Shioda, PhD, DVM, MPH1,*,
- Alexander Breskin, PhD, MPH2,
- Pravara Harati3,
- Allison Chamberlain, PhD, MS4,
- Benjamin A Lopman, PhD4 and
- Elizabeth T. Rogawski McQuade, PhD, MSPH4
- 1Gangarosa Department of Environmental Health and Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
- 2Regeneron Pharmaceuticals, Tarrytown, NY, USA; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- 3Georgia Department of Public Health, Atlanta, GA, USA
- 4Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
- ↵*CORRESPONDING AUTHOR
Kayoko Shioda, PhD, DVM, MPH, Gangarosa Department of Environmental health and Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road NE, Atlanta, GA 30333, Email: kayoko.shioda{at}aya.yale.edu
Posted March 08, 2023.
Comparative Effectiveness of Alternative Intervals between First and Second Doses of the mRNA COVID-19 Vaccines: a Trial Emulation Approach
